BTK and B-cell chronic lymphocytic leukemia: Non-covalent inhibitors of BTK, such as pirtobrutinib 8 [20] and fenebrutinib 9 [21], are also effective in the treatment of CLL [22], and they have been evaluated in relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) and CLL [23].